Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
recAP pharmacokinetics, safety and tolerability in healthy Japanese subjects
jRCT2031210053Phase 1Completed
- Sponsor
- AM-Pharma
- Start
- May 2021
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in sepsis-associated acute kidney injury (S-AKI) (6 arms), sponsored by AM-Pharma. Primary endpoint: Primary PK endpoints. Started May 2021; status: completed.
02
Conditions
sepsis-associated acute kidney injury (S-AKI)
Beyond the preview
Go deeper on jRCT2031210053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210053.